Aggarwal @docrota et al. RCT abatacept in IIM - 52 week results. IMACS DOI, FI-2, HAQ-DI, CDASI, TIS, MRC response all numerically better, some statistically significant. There looks like a real effect across all subtypes. @RheumNow #ACR22 Abstr#2237 https://t.co/NdkH8BnSEw https://t.co/l7ufagjniX

Kim et al. After first episode VZV in RA or UC treated with JAKi, continued JAKi use does not increase reactivation compared to cessation. @RheumNow #ACR22 Abstr#2220 https://t.co/zx96xgkySU https://t.co/KdniDGCUgI

#ACR22 Abstr#1656 Promising therapy for #lupus. Cenerimod, S1P1 modulator, controls lymphocyte trafficking out of lymph nodes into blood. Phase 2 dose-ranging RCT didn't meet primary endpoint (adjusted for multiple testing) but mSLEDAI-2K reduced in 4mg dose vs PBO @RheumNow https://t.co/YnENTkqClk

Some RA patients do well. Some do badly, and get frail even before the age of 65 (6% of pts). These are the ones that get hit by infections with b/tsDMARDs: see below from MarketScan data. These are the patients we need to watch & protect! ABST2217 @NamrataRheum #ACR22 @RheumNow https://t.co/DXZjFDnCcn

Nakafero et al. Self-controlled case series analysis. No increased risk RMD flare with SARS-CoV-2 vaccination. In fact reduced risk! aIRR 0.89(0.80-0.98). No evidence in any of multiple subanalyses either @RheumNow #ACR22 Abstr#2194 https://t.co/r5pOkdjnR1 https://t.co/YpwMkJ3WVe

ACRTIC REWIND finds RA pts w/ sustained clinical remission for at least two years and successfully tapered csDMARDs to half-dose, majority of pts who discontinued csDMARDs remained flare free for 12 months. Abs 2013 #ACR22 @RheumNow https://t.co/HsQz0cJznp https://t.co/QceTXJZiFF

🌱Plants for joints 🌱 👉16wk 👉whole food plant based diet + Phys activity + stress Mx 👉 metabolic syndrome assoc OA hip/knee 💥 substantial ⬇️ pain + stiffness 💥⬆️ physical function #ACR22 @RheumNow Abst 1644 https://t.co/u6UufpbrcC

Thanks for the love #Philly #ACR22 @RheumNow check out our coverage by logging on to https://t.co/xF1bNhZB1C! https://t.co/ncBM0icZ3c

Retrospective cohort study 132 immune checkpoint inhibitor arthritis pts Rx with either TNFi ± MTX or IL6Ri ± MTX have a shorter time to cancer progression but faster arthritis control than patients Rx with MTX alone. Bass A Abs#1669 https://t.co/h0Nq6yd2wf #ACR22 @RheumNow https://t.co/XfXMtdbCPB

Wallace @BethIWallace et al. Time dependent evaluation GCs and MACE in RA. Effect of steroids in previous 6 months on MACE risk in next 6 months. Odds MACE (vs no steroid) 1.54 (1-7 days) 1.78 (8-90 days) 2.17 (>90 days) @RheumNow #ACR22 Abstr#2219 https://t.co/w4gCgjeSNa https://t.co/TQ9pufGtBD